# A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults

> **NCT06680128** · PHASE1,PHASE2 · RECRUITING · sponsor: **SK Bioscience Co., Ltd.** · enrollment: 402 (estimated)

## Conditions studied

- Japanese Encephalitis Virus Disease

## Interventions

- **BIOLOGICAL:** GBP560-A
- **BIOLOGICAL:** GBP560-B
- **BIOLOGICAL:** IXIARO
- **BIOLOGICAL:** IMOJEV
- **BIOLOGICAL:** Normal Saline (Placebo)

## Key facts

- **NCT ID:** NCT06680128
- **Lead sponsor:** SK Bioscience Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-24
- **Primary completion:** 2026-06-26
- **Final completion:** 2028-03-19
- **Target enrollment:** 402 (ESTIMATED)
- **Last updated:** 2025-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06680128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06680128, "A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06680128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*